• br AD and COX LOX pharmacology Early studies

  2024-05-13

  

  AD and COX/5-LOX pharmacology Early studies on the role of cyclooxygenases in AD were inspired by epidemiological data suggesting that COX inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs) could be beneficial in AD patients (Lucca et al., 1994, McGeer et al., 1990). This line of re

• Cobimetinib australia Phospholipases cleave membrane phospho

  2024-05-13

  

  Phospholipases cleave membrane phospholipids from inflammatory cells, activated platelets, erythrocytes, adipocytes and cancer Cobimetinib australia (Aoki et al., 2008, Neidlinger et al., 2006). Several reports have analysed the role of LPA and its receptors in the pathogenesis of RA. Zhao et al.

• In the current study we showed that known inhibitors of

  2024-05-13

  

  In the current study, we showed that known inhibitors of the F-ATPase and ionophores affect the growth of P. gingivalis and its plasma membrane ATPase, suggesting that the membrane ATPase can be a target for anti-periodontitis agents. We also identified stilbenoids that strongly inhibit the growth o

• br Introduction Lung cancer is the leading cause of cancer

  2024-05-13

  

  Introduction Lung cancer is the leading cause of cancer death worldwide and is one of the most refractory of solid tumors along with pancreatic cancer. Since 1975 there have been notable improvements in the 5-year survival rate of patients with lung cancer [1]. This improvement in survival is tho

• br ACL Inhibition Lowering Blood LDL

  2024-05-13

  

  ACL Inhibition: Lowering Blood LDL-C to Reduce ASCVD Risk Given its strategic position in the lipid biosynthesis pathway, ACL has been considered an attractive target for lipid-lowering even before statins and their effects on cholesterol homeostasis were elucidated (Box 2). Cells carefully maint

• The skin permeability barrier is important for

  2024-05-13

  

  The skin permeability barrier is important for the prevention of loss of water and electrolytes from inside the body and for protection against the invasion of external pathogens, allergens, and harmful compounds. Multi-layered lipids, called lipid lamellae, are present in the outermost cell layer o

• Somatostatin analogs also bind to

  2024-05-11

  

  Somatostatin analogs also bind to somatostatin receptors. It has been reported that octreotide has a high affinity for hSSTR2, moderate affinity for hSSTR3 and hSSTR5, and does not bind to hSSTR1 or hSSTR4 (Ben-Shlomo and Melmed 2008). Compared to octreotide, pasireotide displays 40-, 30-, and 5-fol

• br Acknowledgements We would like to thank Dr

  2024-05-11

  

  Acknowledgements We would like to thank Dr. Thomas Blanpied, Sai Sachin Divakaruni, Dr. Helmut Kessels, Feline Lindhout, Dieudonnée van de Willige, and all members of the MacGillavry lab for discussions and critical reading of the manuscript. This work was supported by NWO (ALW-VENI 863.13.020, A

• br Conclusions br Acknowledgements We would

  2024-05-11

  

  Conclusions Acknowledgements We would like to thank the members of the Bergmann lab for fruitful discussions in the course of this work. This work was supported by the National Institute of General Medical Sciences (NIGMS) under award number R35 GM118330. The content is solely the responsibili

• The current antifungal pipeline contains

  2024-05-11

  

  The current antifungal pipeline contains several categories of compounds at different stages of development [1], [9], [10], [96]. In Table 1 we summarize the most promising antifungal molecules that are in preclinical and in clinical development. Several compounds in the pipeline are derivatives of

• br Brain Angiotensin II receptors The information above

  2024-05-11

  

  Brain Angiotensin II receptors The information above leaves Angiotensin II receptors as the only RAAS components for which localization, regulation of expression and function in the ketorolac toradol has been convincingly demonstrated, with the use of quantitative film and emulsion autoradiograp

• br Conclusion br Acknowledgement This

  2024-05-11

  

  Conclusion Acknowledgement This study was supported by NIH/NINDSR01 NS036812-16. Introduction Lipoxygenases (LOXs) are a heterogeneous family of enzymes that catalyze the peroxidation of polyunsaturated fatty acids (PUFAs). By oxidizing free PUFAs, they were shown to contribute to the gene

• Introduction Lipoxygenases LOXs are key enzymes that catalyz

  2024-05-11

  

  Introduction Lipoxygenases (LOXs) are key enzymes that catalyze the polyunsaturated fatty acids (PUFAs) such as arachidic caspase inhibitor (AA), linoleic acid (LA) and others unsaturated fatty acids (Brash, 1999). LOXs are expressed in immune, neural, epithelial, tumor cells and other cells (Clae

• br ABCA and cancer drug response Overall

  2024-05-11

  

  ABCA2 and cancer drug response Overall, the expression of ABC transporters has been linked with multidrug resistance phenotypes through the efflux of drugs via ATP-dependent transport. For example, 13 distinct transporters (ABCA2, ABCB1, ABCB4, ABCB11, ABCC1–6 ABCC10, ABCC11 and ABCG2) have been

• br Conflicts of interest br Newly

  2024-05-11

  

  Conflicts of interest Newly Identified Mechanisms of APN Resistance Hold Therapeutic Potential APN, APN Receptors, and APN Cardiovascular Protection APN Resistance in Cardiovascular Disease The Molecular Mechanisms of APN Resistance Concluding Remarks and Future Directions Finally,

16455 records 175/1097 page Previous Next First page 上5页 171172173174175 下5页 Last page